Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.

Weekly muscle-strengthening exercise helps prevent hypertension in adults

18 Jul 2020

Weekly muscle-strengthening exercise, regardless of frequency, leads to a lower prevalence of hypertension compared with no exercise at all, according to a recent study involving 1.5 million adults.

The investigators pooled data from four US health surveillance surveys (2011-2017; n=1,539,309; age, ≥18 years) in this cross-sectional study. They evaluated the frequency of muscle-strengthening exercise and self-reported clinically diagnosed hypertension (n=431,313; 28 percent) using the same items across each survey.

The prevalence ratios of hypertension (outcome variable) across muscle-strengthening exercise (exposure variables: 0 [reference]; 1 to ≥7 times/week) were determined by generalized linear models using Poisson regression with robust error variance, adjusting for potential cofounders.

The adjusted prevalence ratios for hypertension among the groups engaging in muscle-strengthening exercise one, two, three, four, five, six, and at least seven times/week were 0.67 (95 percent confidence interval [CI], 0.66–0.68), 0.67 (95 percent CI, 0.67–0.68), 0.70 (95 percent CI, 0.69–0.70), 0.61 (95 percent CI, 0.60–0.63), 0.62 (95 percent CI, 0.61–0.64), 0.60 (95 percent CI, 0.58–0.62), and 0.83 (95 percent CI, 0.82–0.84), respectively, in comparison to those doing none.

These associations persisted even after stratification for sociodemographic factors (ie, age and sex), lifestyle characteristics (ie, aerobic exercise, body mass index, self-rated health, smoking, alcohol), and comorbidities (eg, arthritis, diabetes, depression).

“Longitudinal studies and large-scale muscle-strengthening exercise interventions with population representative samples are needed to confirm these preliminary cross-sectional observations,” the investigators said.

“Clinical evidence suggests that muscle-strengthening exercise (using weight machines/body weight exercises) may be an important antihypertensive lifestyle therapy,” they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.